Wegovy Pill UK Approval: What Changed and What It Means

Why the approval date matters more than the headline

Regulatory approvals often get reduced to a single sentence in the news. This one deserves a closer look. The MHRA's 11 June 2026 decision was not simply a rubber stamp on a product the rest of the world had already adopted: the UK was the first country in Europe to grant a licence for an oral GLP-1 medicine in weight management. That distinction reflects how thoroughly the evidence was reviewed, the MHRA looked at the OASIS 4 trial data, the safety profile, and the formulation's absorption mechanism before granting approval.

Semaglutide in tablet form uses a co-formulation with an absorption enhancer called SNAC, which allows the molecule to pass through the stomach lining rather than being broken down before it can work. Without that mechanism, oral semaglutide simply would not be bioavailable at meaningful levels. The approval confirms that the formulation clears the bar for safety and efficacy set by the UK regulator. This page explains the science behind oral semaglutide in more accessible terms if you want the full picture before deciding anything.

The medicine is licensed for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related health condition such as high blood pressure, raised cholesterol or type 2 diabetes. Those thresholds sit alongside reduced-calorie eating and increased activity, treatment is an addition to lifestyle changes, not a replacement for them.

What the trial results actually showed

The OASIS 4 trial ran for 64 weeks and involved 307 adults with obesity or overweight and at least one weight-related condition, none of whom had type 2 diabetes. It compared the active tablet against placebo, alongside lifestyle support. Average weight loss across the semaglutide group (regardless of how consistently people took the treatment) was around 13.6%, compared with approximately 2.4% in the placebo group. Among participants who remained fully adherent throughout the trial, the average loss was around 16.6%.

A question our prescribers hear most weeks is whether the tablet works as well as the injection. The honest answer is that the 64-week figure for the tablet sits below the 68-week average of roughly 15% seen in the STEP 1 trial for the 2.4mg weekly injection, though comparisons across separate trials are always imperfect. The populations differ slightly, the durations differ slightly, and individual response varies considerably. What the trial does confirm, as the MHRA's semaglutide approval announcements make clear, is that this is a clinically meaningful licensed option, not a watered-down alternative.

The most common side effects in OASIS 4 were gastrointestinal: nausea, vomiting, diarrhoea and constipation appeared in about 74% of those taking the active tablet, though for most participants these were mild to moderate and settled over time. That GI rate is higher than typically reported for the injection, which is worth knowing before you commit. More detail on the side-effect profile of semaglutide tablets is covered separately.

How this fits the NHS landscape right now

At the time of writing, Wegovy tablets are available only through private prescription. An MHRA approval opens the door legally; it does not automatically fund NHS access. For that, a NICE technology appraisal is needed, followed by NHS commissioning guidance. Given that NICE's appraisal of the Wegovy injection (TA875) took several years to translate into meaningful NHS availability, it is realistic to expect a similar timeline for the tablet. The NHS is gradually expanding access to weight-loss medicines (this overview of licensed weight-loss treatments sets out the current landscape clearly) but waiting lists for specialist services remain long in most areas.

For people who do not meet the NHS criteria or do not want to join a waiting list, a private prescription route through a regulated pharmacy is the alternative. Any online pharmacy dispensing these medicines should be verifiable on the GPhC's public register; that check takes thirty seconds and is worth doing. Prescription-only medicines cannot legally be sold to you without a clinical assessment, so any seller that skips that step is a red flag, whatever price they advertise.

Making the decision: injection, tablet, or neither yet

The UK-approved Wegovy pills give people who would prefer not to inject a licensed, evidence-backed option that did not exist six months ago. It also suits anyone who travels frequently, since the tablets need no refrigeration, a genuine practical advantage over the pen, which requires a cold chain. The dose escalation starts at 1.5mg daily, moving through 4mg and 9mg to the 25mg maintenance dose, with at least a month at each level. The full schedule and how to take the tablet correctly are set out in the prescribing information; a prescriber will walk you through it at consultation. This page covers the dosing schedule in detail.

That said, the tablet is not automatically the better choice. Some people tolerate the injection very well and are happy with the pen. Others will find daily timing (taken first thing on a completely empty stomach, with nothing but a small sip of water, waiting at least 30 minutes before any food, drink or other medicines) harder to build into a routine than a once-weekly injection. Neither answer is universal. If you are currently on the 2.4mg injection and doing well, switching to the tablet should only happen after a clinical conversation, not on impulse.

On cost, the private price of a new licensed treatment at launch is rarely low. A realistic look at Wegovy tablet pricing in the UK is on that page. At nume, one transparent price covers your consultation, prescription, and free tracked delivery, no subscription, no hidden fees. If you would like to find out whether the tablet is suitable for you, speak to our prescribers through a free consultation and get a same-day clinical review.